Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors

類似資料

• Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis
  著者:: Park, Hyo Jung, 等
  出版事項: (2020)
• Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis
  著者:: Yoon, Byung Woo, 等
  出版事項: (2019)
• Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma
  著者:: Kim, Jwa Hoon, 等
  出版事項: (2021)
• Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations
  著者:: Yoon, Shinkyo, 等
  出版事項: (2017)
• Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505)
  著者:: Yoon, Shinkyo, 等
  出版事項: (2017)